These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 29999163

  • 1. [Atypical hemolytic uremic syndrome. Report of two cases treated with Eculizumab].
    Tagle R, Rivera G, Walbaum B, Sepúlveda RA.
    Rev Med Chil; 2018 Feb; 146(2):254-259. PubMed ID: 29999163
    [Abstract] [Full Text] [Related]

  • 2. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 3. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [Abstract] [Full Text] [Related]

  • 4. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A, Nayer A, Haas CS.
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 6. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N, Ayer M, Ergen A, Ozturk S.
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [Abstract] [Full Text] [Related]

  • 7. [Atypical hemolytic uremic syndrome].
    Sepúlveda RA, Tagle R, Jara A.
    Rev Med Chil; 2018 Jun; 146(6):770-779. PubMed ID: 30148909
    [Abstract] [Full Text] [Related]

  • 8. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 9. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD.
    Praxis (Bern 1994); 2016 Mar 30; 105(7):389-96. PubMed ID: 27005733
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Mar 30; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

  • 11. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab.
    Gately R, San A, Kurtkoti J, Parnham A.
    Nephrology (Carlton); 2017 Feb 30; 22 Suppl 1():32-35. PubMed ID: 28176475
    [Abstract] [Full Text] [Related]

  • 12. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan 30; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 13. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA.
    BMC Nephrol; 2019 Apr 10; 20(1):125. PubMed ID: 30971227
    [Abstract] [Full Text] [Related]

  • 14. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
    Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.
    J Med Case Rep; 2014 Sep 14; 8():307. PubMed ID: 25219386
    [Abstract] [Full Text] [Related]

  • 15. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M, Go RS, Willrich MAV.
    J Immunol Methods; 2018 Oct 14; 461():15-22. PubMed ID: 30031798
    [Abstract] [Full Text] [Related]

  • 16. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.
    Intern Med J; 2015 Oct 14; 45(10):1054-65. PubMed ID: 26247170
    [Abstract] [Full Text] [Related]

  • 17. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.
    Ther Apher Dial; 2018 Apr 14; 22(2):178-188. PubMed ID: 29250893
    [Abstract] [Full Text] [Related]

  • 18. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 Apr 14; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 19. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 14; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

  • 20. [Recurrent atypical hemolytic uremic syndrome after renal transplantation: treatment with eculizumab].
    Latzke AB, Fernández P, Chiurchiu C, Sarmantano D, De Arteaga J, Douthat W, De la Fuente J.
    Medicina (B Aires); 2018 Jan 14; 78(2):119-122. PubMed ID: 29659362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.